Literature DB >> 18094029

Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome.

Farid Nakhoul1, Eliyahu Khankin, Afif Yaccob, Hiroshi Kawachi, Tony Karram, Huda Awaad, Nakhoul Nakhoul, Aaron Hoffman, Zaid Abassi.   

Abstract

Nephrotic syndrome (NS) is a clinical state characterized by massive proteinuria and edema. It is believed that nephrin and podocin are involved in the development of proteinuria. The proteinuria and effects of eplerenone alone or combined with enalapril on nephrin/podocin abundance in rats with NS have not yet been studied. Therefore, the present study was designed to examine the early (beginning 2 days before NS induction) and late (beginning 2 wk after NS induction) effects of eplerenone and enalapril, alone or combined, on proteinuria and nephrin/podocin abundance in rats with adriamycin-induced NS. Adriamycin caused a significant increase in daily protein excretion (U(pr)V; from 26.96 +/- 3.43 to 958.57 +/- 56.7 mg/day, P < 0.001) and cumulative proteinuria [from 900.33 +/- 135.5 to 22,490.62 +/- 931.26 mg (P < 0.001)] during 6 wk. Early treatment with enalapril significantly decreased U(pr)V from 958.6 +/- 56.7 to 600.31 +/- 65.13 mg/day (P < 0.001) and cumulative proteinuria to 12,842.37 +/- 1,798.17 mg/6 wk (P < 0.001). Similarly, early treatment with eplerenone produced a profound antiproteinuric effect: U(pr)V decreased from 958.57 +/- 56.7 to 593.38 +/- 21.83 mg/day, P < 0.001, and cumulative proteinuria to 16,601.84 +/- 1,334.31 mg/6 wk; P < 0.001. An additive effect was obtained when enalapril and eplerenone were combined: U(pr)V decreased from 958.57 +/- 56.69 to 424.17 +/- 38.54 mg/day, P < 0.001, and cumulative protein excretion declined to 10,252.88 +/- 1,011.3 mg/6 wk, P < 0.001. These antiproteinuric effects were associated with substantial preservation of glomerular nephrin and podocin. In contrast, late treatment with either enalapril or eplerenone alone or combined mildly decreased U(pr)V and cumulative proteinuria. Thus pretreatment with eplerenone or enalapril is effective in reducing daily and cumulative protein excretion and preservation of nephrin/podocin. More profound antiproteinuric effects were obtained when enalapril and eplerenone were combined.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18094029     DOI: 10.1152/ajprenal.00524.2007

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  6 in total

Review 1.  Mineralocorticoid receptor activation as an etiological factor in kidney diseases.

Authors:  Kohei Ueda; Miki Nagase
Journal:  Clin Exp Nephrol       Date:  2013-07-06       Impact factor: 2.801

Review 2.  Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease.

Authors:  Miki Nagase; Toshiro Fujita
Journal:  Nat Rev Nephrol       Date:  2013-01-08       Impact factor: 28.314

Review 3.  Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2013-03-08       Impact factor: 3.714

Review 4.  Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.

Authors:  Sankar D Navaneethan; Sagar U Nigwekar; Ashwini R Sehgal; Giovanni F M Strippoli
Journal:  Clin J Am Soc Nephrol       Date:  2009-03-04       Impact factor: 8.237

5.  Effects of spironolactone and losartan on diabetic nephropathy in a type 2 diabetic rat model.

Authors:  Mi Young Lee; Myoung Sook Shim; Bo Hwan Kim; Soon Won Hong; Ran Choi; Eun Young Lee; Soo Min Nam; Gun Woo Kim; Jang Yel Shin; Young Goo Shin; Choon Hee Chung
Journal:  Diabetes Metab J       Date:  2011-04-30       Impact factor: 5.376

6.  Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.

Authors:  Edmund Ym Chung; Marinella Ruospo; Patrizia Natale; Davide Bolignano; Sankar D Navaneethan; Suetonia C Palmer; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2020-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.